Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated a new aqueous-based nanosuspension of minoxidil for treating androgenetic alopecia and reported it was as effective as the commercial product but had better safety and tolerability, potentially improving patient compliance.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

This study developed a new suspended ointment formulation containing neomycin sulfate and triamcinolone acetonide, which showed promise for treating neurodermatitis and chronic eczema by ensuring stable composition, effective skin penetration, and no skin irritation.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This study reported the development of a pH-responsive microreactor that effectively targets infections by eradicating over 99.9% of MRSA and reprogramming the immune response to promote healing, achieving complete infection clearance and tissue regeneration in a 7-day period.

This study developed a NIR light-triggered NO-releasing hydrogel that promotes angiogenesis, repairs damaged dermal papilla cells, reduces inflammation, and improves the nutrient supply and follicular environment in animal models, offering a promising treatment strategy for androgenic alopecia.

This article reviews the potential uses of PDRN in regenerative and aesthetic medicine, noting promising results in various treatments but highlighting the need for further long-term studies to confirm their safety and effectiveness.

In this study, researchers developed a near-infrared-responsive nanoplatform that synergistically enhances chronic wound healing by accelerating mitochondrial restoration and immune modulation, leading to enhanced wound repair and high-quality healing in diabetic rat models.

In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.

In this study, a new formulation of all-trans retinoic acid bound to polyvinyl alcohol showed reduced skin inflammation and sustained drug release for up to six days compared to free ATRA in vitro and in vivo.

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

Among participants in a 26-week trial, this study by REVIAN Inc. reported that their REVIAN RED dual wavelength LED light treatment for androgenetic alopecia was both safe and effective at the 16-week mark.

This study evaluated a hydrogel containing extracts from azadirachta indica and tridax procumbens for treating seborrheic dermatitis, finding it passed various tests, including skin irritation and stability, suggesting potential future applications in herbal formulations.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

This study reports on a patient's case with support data available on request but provides no new research findings.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that ALRV5XR showed the highest efficacy for terminal hair regrowth in both men and women with androgenetic alopecia, with less treatment resistance compared to other therapies.

This study reported a drug-induced pityriasis rubra pilaris-like eruption in a patient treated with sorafenib, suggesting a possible effect of sorafenib on keratinocyte biology.

This study found that people taking Serenoa repens for more than 14 days had a higher likelihood of serious adverse reactions, particularly when also using multiple or interacting supplements, although higher SR doses were linked to lower risk.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

This study found that RADA-PRG hydrogels enhanced skin-derived precursor cell proliferation and improved hair follicle neogenesis in mice, suggesting potential use as a scaffold material in tissue engineering.

In this study, a topical hair growth serum containing ingredients like procapil and redensyl was found to be safe and effective for subjects with androgenic alopecia, significantly improving hair density, thickness, and Anagen:Telogen ratio after 120 days, with no observed adverse effects.

This study shares preliminary findings that roxithromycin treatment tendentially increased hair shaft production and altered the hair follicle microbiota in human hair ex vivo, with substantial inter-individual differences observed.

In this study, researchers developed a novel temperature-sensitive biopolymer-based drug delivery system that enhanced the transdermal delivery of ISX9, a neurogenesis inducer, resulting in more effective hair follicle regrowth and signal pathway activation in vivo compared to traditional topical application.

This article discusses a novel multi-targeting approach to treating hair loss using standardized nutraceuticals but reports no new clinical results.

The researchers reported that zinc carbonate nanoparticles stabilized with polyvinylpyrrolidone did not show local irritant or skin-resorptive effects in preclinical tests on rabbits and rats.